The role of anti-Galα1-3Gal antibodies in acute vascular rejection and accomodation of xenografts

被引:116
作者
Lin, SS
Hanaway, MJ
Gonzalez-Stawinski, G
Lau, CL
Parker, W
Davis, RD
Byrne, GW
Diamond, LE
Logan, JS
Platt, JL
机构
[1] Mayo Clin, Dept Surg, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA
[3] Mayo Clin, Dept Pediat, Rochester, MN 55905 USA
[4] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
[5] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA
[6] Nextran Inc, Princeton, NJ 08540 USA
关键词
D O I
10.1097/00007890-200012270-00002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. A major impediment to the transplanting of porcine organs into humans is the susceptibility of porcine organs to acute vascular rejection, which can destroy a vascularized xenograft over a period of hours to days. Acute vascular rejection of porcine-to-primate xenografts is thought to be triggered by binding of xenoreactive antibodies to the graft. We tested whether antibodies, binding to Gal alpha1-3Gal epitopes in porcine tissue, initiate this phenomenon. Methods and results. Specific depletion of anti; Gal alpha1-3Gal antibodies from the blood of baboons, using extracorporeal perfusion of separated plasma through columns of Sepharose beads covalently linked to the antigenic trisaccharide, Gal alpha1-3Gal beta1-4GlcAc; averted the development of acute vascular rejection in porcine organs transgenic for human decay-accelerating factor and CD59. More importantly, after immunodepletion was stopped and Gal alpha1-3Gal antibodies were allowed to return, these same organs continued to function and remained pathologically normal and thus seemed to achieve a state of accommodation. Conclusion. These results demonstrate that antiGal alpha1-3Gal antibodies cause acute vascular rejection and suggest that depletion of these antibodies leads to accommodation of the donor cardiac xenograft and could supply an important model for additional study.
引用
收藏
页码:1667 / 1674
页数:8
相关论文
共 44 条
[1]   Delayed xenograft rejection [J].
Bach, FH ;
Winkler, H ;
Ferran, C ;
Hancock, WW ;
Robson, SC .
IMMUNOLOGY TODAY, 1996, 17 (08) :379-384
[2]  
BANNETT AD, 1989, TRANSPLANT P, V21, P783
[3]   Inhibition of xenoreactive natural antibody production by retroviral gene therapy [J].
Bracy, JL ;
Sachs, DH ;
Iacomini, J .
SCIENCE, 1998, 281 (5384) :1845-1847
[4]   Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage [J].
Byrne, G ;
McCurry, KR ;
Martin, MJ ;
McClellan, SM ;
Platt, JL ;
Logan, JS .
TRANSPLANTATION, 1997, 63 (01) :149-155
[5]  
COOPER DKC, 1988, J HEART TRANSPLANT, V7, P238
[6]   THE HUMORAL IMMUNE-RESPONSE IN HUMANS FOLLOWING CROSS-PERFUSION OF PORCINE ORGANS [J].
COTTERELL, AH ;
COLLINS, BH ;
PARKER, W ;
HARLAND, RC ;
PLATT, JL .
TRANSPLANTATION, 1995, 60 (08) :861-868
[7]  
Cozzi E, 1997, XENOTRANSPLANTATION, P665
[8]   THE POTENTIAL SUPPLY OF ORGAN DONORS - AN ASSESSMENT OF THE EFFICIENCY OF ORGAN PROCUREMENT EFFORTS IN THE UNITED-STATES [J].
EVANS, RW ;
ORIANS, CE ;
ASCHER, NL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (02) :239-246
[9]   VARIATION IN EXPRESSION OF PORCINE XENOGENEIC ANTIGENS [J].
GELLER, RL ;
RUBINSTEIN, P ;
PLATT, JL .
TRANSPLANTATION, 1994, 58 (03) :272-277
[10]  
GEWURZ HENRY, 1967, TRANSPLANTATION, V5, P1296, DOI 10.1097/00007890-196709000-00008